Jan 20 |
Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares
|
Jan 3 |
Pliant Therapeutics: Targeting Idiopathic Pulmonary Fibrosis
|
Jan 3 |
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
Nov 13 |
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
|
Nov 9 |
Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.08
|
Nov 9 |
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
|
Nov 9 |
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
|
Nov 7 |
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
Nov 6 |
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
|